Company Information

  

Address: 79 T.W. ALEXANDER DRIVE
4501 RESEARCH COMMONS, SUITE 100 
City: RESEARCH TRIANGLE PARK 
State: NC 
Zip Code: 27709 
Telephone: 919-213-9835 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. Our product portfolio is built on a drug discovery platform that targets key cellular pathways with proprietary medicinal chemistry. Our therapies are designed to enable more effective combination treatment strategies and improve outcomes for patients across multiple oncology indications. We were incorporated under the laws of the State of Delaware in May 2008 under the name "G-Zero Therapeutics, Inc." In September 2012, we changed our name to "G1 Therapeutics, Inc." Our principal executive offices are located at 79 T.W. Alexander Drive, 4501 Research Commons, Suite 100, Research Triangle Park, NC 27709, and our telephone number is (919) 213-9835. We manage our operations as a single segment for the purposes of assessing performance and making operating decisions.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/20186.97NA5.32

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.27Total Liab/Total Assets0.11
Net Inc/Total Assets-0.57Total Liab/Inv Cap0.13
Net Inc/Inv Cap-0.64Total Liab/Comm Equity0.05
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio8.94
Inventory TurnoverNACurrent Ratio8.94
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.38 2.21 1.88 1.71
Operating Income -20.73 -17.28 -15.93 -15.38
Interest Exp NA NA NA NA
Pretax Income -20.41 -16.98 -15.60 -15.19
Other Income 0.32 0.30 0.33 0.19
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -20.41 -16.98 -15.60 -15.19

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 194.39 103.81 118.38 132.68
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 195.18 104.66 119.04 133.77
Net Property, Plant & Equipment 0.56 0.51 0.52 0.33
Total Assets 195.74 105.17 119.55 134.10
Liabilities        
Accounts Payable 12.51 11.70 10.42 10.41
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 12.51 11.70 10.42 10.41
Long-Term Debt NA NA NA NA
Total Liabilities 12.59 11.78 10.42 10.41
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -149.53 -129.12 -112.14 -96.54
Treasury Stock -0.01 -0.01 -0.01 -0.01
Total Stockholders' Equity 183.16 93.39 109.13 123.69
Total Liabilities and Stockholders' Equity 195.74 105.17 119.55 134.10

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -18.11 -14.75 -13.76 -12.74
Net Cash Provided by Investing Activities -0.07 -0.02 -0.24 -0.02
Net Cash Provided by Financing Activities 108.76 0.20 -0.30 107.71

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20150.52-20.26--
12/20160.00-30.29--
12/20170.00-60.12--
Growth Rates-100.00----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional03/31/189919,99861.15




Report Date : 6/18/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.